Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip C Prorok

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
Statistics in Medicine|May 9, 2009
Effect of length biased sampling of unobserved sojourn times on the survival distribution when disease is screen detectedKaren Kafadar, Philip C Prorok
Statistics in Medicine|December 18, 2002
Alternative definitions of comparable case groups and estimates of lead time and benefit time in randomized cancer screening trialsKaren Kafadar, Philip C Prorok
Statistics in Medicine|January 29, 2005
Computational methods in medical decision making: to screen or not to screen?Karen Kafadar, Philip C Prorok
Journal of Medical Screening|August 26, 2020
Breast cancer overdiagnosis in stop-screen trials: More uncertainty than previously reportedStuart G Baker, Philip C Prorok
Journal of Medical Screening|April 8, 2009
On testing independence of repeated screening testsJian-Lun Xu, Philip C Prorok
Seminars in Oncology|August 17, 2010
Cancer screening trials: nuts and boltsPhilip C Prorok, Pamela M Marcus
Statistics in Medicine|July 23, 2003
Modelling and analysing exchangeable binary data with random cluster sizesJian-Lun Xu, Philip C Prorok
Annals of Internal Medicine|April 21, 2018
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO TrialsPhilip C Prorok, Anthony B Miller
Clinical Trials (London, England)|January 25, 2014
Considerations in the design of randomized trials to screen for type 2 diabetesJustin B Echouffo-Tcheugui, Philip C Prorok
Journal of the National Cancer Institute|October 9, 2024
Design of randomized controlled trials to estimate cancer-mortality reductions from multicancer detection screeningPing Hu, Philip C Prorok, Hormuzd A Katki
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
Statistics in Medicine|May 9, 2009
Effect of length biased sampling of unobserved sojourn times on the survival distribution when disease is screen detectedKaren Kafadar, Philip C Prorok
Statistics in Medicine|December 18, 2002
Alternative definitions of comparable case groups and estimates of lead time and benefit time in randomized cancer screening trialsKaren Kafadar, Philip C Prorok
Statistics in Medicine|January 29, 2005
Computational methods in medical decision making: to screen or not to screen?Karen Kafadar, Philip C Prorok
Journal of Medical Screening|August 26, 2020
Breast cancer overdiagnosis in stop-screen trials: More uncertainty than previously reportedStuart G Baker, Philip C Prorok
Journal of Medical Screening|April 8, 2009
On testing independence of repeated screening testsJian-Lun Xu, Philip C Prorok
Seminars in Oncology|August 17, 2010
Cancer screening trials: nuts and boltsPhilip C Prorok, Pamela M Marcus
Statistics in Medicine|July 23, 2003
Modelling and analysing exchangeable binary data with random cluster sizesJian-Lun Xu, Philip C Prorok
Annals of Internal Medicine|April 21, 2018
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO TrialsPhilip C Prorok, Anthony B Miller
Clinical Trials (London, England)|January 25, 2014
Considerations in the design of randomized trials to screen for type 2 diabetesJustin B Echouffo-Tcheugui, Philip C Prorok
Journal of the National Cancer Institute|October 9, 2024
Design of randomized controlled trials to estimate cancer-mortality reductions from multicancer detection screeningPing Hu, Philip C Prorok, Hormuzd A Katki
Pageof 9